W W W . C B I N E T . C O M / A C C O U N T I N G

Most Customizable Congress Yet! Features 4 Pre-Conference Summits, 5 In-Depth Workshops and 2 Track Options! Plus, Earn CPE Credits!

MARCH 16-18, 2015 | HYATT REGENCY PENN’S LANDING | PHILADELPHIA, PA

• Gross-to-Net models for forecasting Coverage Gap and Branded Pharma Fee

• SEC comment letter topic analysis — MD&A, Revenue Recognition, Intangibles, Fair Value Measurements

• Internal Control frameworks that map and mitigate business risks

• Documentation strategies aligned with SOX and COSO requirements

• Transformative approaches to tax strategy

• Deal activity analysis and M&A outlook

• Valuation models for IPR&D assets, contingent consideration and impact on deal strategy

• Transaction accounting for in/out licensing arrangements

• Contract review for royalty agreements and exercising audit rights

• New revenue standard and strategies for assessment, application and implementation

• Risk-share R&D models and asset transactions

• Accounting approaches and valuation for stock options and equity compensation

PIONEERING PERSPECTIVES INCLUDE:

Actavis, plc • Alexion • Amgen • Amicus Therapeutics • Atlas Ventures • Bristol-Myers Squibb

Charles River Labs • Deloitte • Eli Lilly & Co. • Epizyme • Ernst & Young LLP • FASB

Gilead Sciences • Glycomimetics • Impax Labs • Intercept Pharmaceuticals • Johnson & Johnson

J.P. Morgan • KPMG • Merck & Co • Mylan • Regeneron • Sunovion

TetraLogic Pharmaceuticals • PCAOB • PwC • SEC

R E G I S T E R B Y J A N U A R Y 1 6 , 2 0 1 5 A N D S A V E $ 3 0 0 !

LEAD SPONSOR STRATEGIC CORPORATE SPONSOR

STRATEGIC SILVER SPONSOR

LIFE SCIENCES

CONGRESSACCOUNTING & REPORTING

The Industry Standard Accounting Event Driving Practice Alignment and Financial Excellence

CPE Credits Available!Pending Approval

New This Year!PHARMA/BIO

FINANCIAL PLANNING and ANALYSIS

IN-DEPTH CONTENT ON HOT TOPICS, INCLUDING:

A Pre-Congress Summit on March 16th

Additional CPE Credits!Pending Approval

The world’s largest and longest running event for finance and accounting professionals in the life sciences industry ramps up for the most in-depth and impactful event yet! Don’t miss the life science community’s gold standard conference for senior financial reporting, technical accounting and financial analysis professionals, offering industry-specific CPE content, aligning thought leaders on complex technical issues and minimizing diversity of practice.

As the industry undergoes rapid and systemic evolution (due to healthcare reform, M&A, pricing mandates, weakened IP, global expansion, R&D imperatives, cost containment initiatives and increased regulatory scrutiny) CFOs, Controllers and Senior Accounting/Finance professionals are the corporate stewards for new business and growth opportunities. With that comes the heavy burden of enormous practice complexity and risk of financial reporting judgment errors. This event untangles the complex transactions and minimizes the risk.

By Attending You Gain:

1. An opportunity to network, learn and benchmark from hundreds of your industry counterparts to better align thinking on complex issues

2. Insightintothemoststrategicfinancialmindsinlifesciencestobetterpositionyourcompanyforgrowth

3. Industry-specificcontentthatearnscontinuingprofessionaleducationcreditsatthemostin-depthandleading life science-focused event of its kind

W W W. C B I N E T. C O M / A C C O U N T I N G2

WHY YOU SHOULD ATTEND

By BioPharma and for BioPharma — Highly Acclaimed Year Over Year!

“Truly inspiring conference, year after year, to hear from thought leaders in our industry and network regarding hot topics affecting all of us. A must-attend event!”

— 2014 Attendee, Director of Accounting, Sunovion Pharmaceuticals

WHO SHOULD ATTEND

You will benefit from attending this event if you are CFO, CAO, Controller or senior level director from the pharmaceutical or biotech industries with responsibilities or involvement in the following areas:

• Accounting • Auditing

• Finance • Reporting

• Financial Analysis • Forecasting

• Gross-to-net • Corporate Governance

• Sarbanes Oxley • Contracts

This conference will also benefit consultants, software providers and auditing firms that provide outside council to pharmaceutical accounting executives.

BY THE NUMBERS...

of attendees rate this event as “Excellent” and “Very Good.”

OVER 400 ATTENDEES ATTEND EACH YEAR

Representing over life science companies

of attending companies send teams

of participants are from PHARMA/BIOTECH/DEVICE companies

over 90

> %

90OVER

MONDAY CHOICES

FULL-DAY SUMMIT

PHARMA/BIO FINANCIAL PLANNING AND ANALYSIS SUMMIT

SEMINARS

FINANCIAL SOLUTIONS — TOOL BOX AND SYSTEM SHOWCASE

A201 BOOT CAMP — ACCOUNTING AND FINANCIAL REPORTING IN LIFE SCIENCE COMPANIES

BGRC EXCELLENCE —MITIGATING RISK AND STRATEGIES FOR INTERNAL CONTROLS

MONDAY, MARCH 16, 2015

CHOOSE FROM MULTIPLE OFFERINGS

9:30 Pharma/Bio Financial Planning, Budgeting and Analysis Summit

11:30 Pre-Congress Learning Seminars

TUESDAY, MARCH 17, 2015

7:30 Breakfast and Main Registration

8:00 Chairperson’s Welcome and Opening Remarks

8:20 OPENING KEYNOTE PANEL

Innovation Tailwinds — New Thinking and Transformative Models Driving the Enterprise and Shareholder Return

9:20 New and Emerging Models for Fueling Growth and Propelling Innovation

10:00 Networking and Refreshment Break

10:30 Industry Luminary Addresses

10:45 Translating Accounting and Technical Regulations into Business and Deal Strategy — The Role of Accounting in Shaping Value

11:15 Transforming and Leading through Transformation — The Role of the Finance Organization During Periods of Growth and Change

11:45 Taking Strides in Corporate Tax Reform — Tax Policy’s Impact on Business Decisions

12:15 Moderated Q&A with Luminary Speakers

12:30 Networking Luncheon

1:30 REGULATORY AND OVERSIGHT EXTENDED SESSION

Review of SEC Comments in Life Sciences and Q&A with SEC

2:30 Technical Guidance Updates from FASB and Initiatives Ahead

2:50 What to Expect from the PCAOB and Impact on Preparers

3:15 Networking and Refreshment Break Hosted by:

3:45 AUDIENCE CHOOSES FROM FIVE AFTERNOON WORKSHOPS

5:45 Close of Workshops / Day One / Cocktail Reception Hosted by:

WEDNESDAY, MARCH 18, 2015

7:30 Breakfast

8:30ATTENDEES CHOOSE BETWEEN 2 TRACKS, WITH OPPORTUNITY TO MOVE BETWEEN SESSIONS

1:00 Close of Conference

AGENDA AT A GLANCE

TUESDAY WORKSHOPS

A VALUATION MODELS AND METHODOLOGIES

B TRANSACTION ACCOUNTING

CREVENUE PLAYBOOK — PROJECT PREPAREDNESS AND CONTRACT REVIEW

D GROSS-TO-NET MASTER CLASS

E ASSET VALUATION AND TAX/TRANSFER PRICING IMPACTS

WEDNESDAY TRACKS

I TECHNICAL ACCOUNTING AND PREPARER BEST PRACTICES

II FINANCE MODELS AND INVESTMENT STRATEGIES

W W W. C B I N E T. C O M / A C C O U N T I N G

“ Extremely insightful to share best practices and lessons learned.”

— 2014 Attendee, Technical Accounting Senior Manager, Cubist Pharmaceuticals

3

FULL-DAY SUMMIT

MONDAY, MARCH 16, 2015 CHOOSE FROM MULTIPLE OFFERINGS

9:30 FP&A Summit Registration

10:30 Chairperson’s Welcome and Opening Remarks

10:50 OPENING ADDRESS New Standards of Excellence for Finance as a Business Partner and Accelerator in Today’s Life Sciences Industry• The evolved role of finance as a business partner• Changing environment and nuanced complexities• Systems to support growth• Transforming the annual planning process• Key success factors for supporting specific

pharmaceutical business areas, such as Marketing, Salesforce, R&D

11:30 PANEL DISCUSSION Industry Excellence Panel — Best Practices for Elevating Financial Planning and Business Analysis• Challenges and tips for success • Overcoming inconsistencies and variability in forecasts • The role of Financial Planning and Analysis in business

development and strategic planning decisions• Internal communication and presentation strategies —

Approaches for presenting financial data and metrics to internal stakeholders

Moderator:Jacqueline Liu, Director Financial Planning and Analysis, Epizyme

Zoran Berkovic, Vice President Finance, Global FPA, Mylan

AnnMarie Earle, Senior Director, Financial and Strategic Planning, Amicus Therapeutics

Carl Hillier, Senior Director, Corporate Financial Analysis, Johnson & Johnson

12:30 Luncheon

1:30 Leveraging Data and Analytics to Optimize Forecasting and Business Planning• Designing systems and processes to maximize

data assets• Identifying revenue drivers with analytics and

operational measures for cost controls• Leveraging information and key analytics to

effectively drive business decisions• Maximizing information for competitive advantage

to deliver growth and operational efficiency

Harold Tamayo, Finance Executive, eQuipus™ Health; former Corporate Vice President of Finance & Corporate Controller, H.D. Smith

2:15 Forecasting, Financial Modeling and Models of Discounted Cash Flow — Strategies for the Intersect of Financial Analysis and Reporting• Key considerations for aspects of financial reporting

that are highly analytical in nature

• Revenue forecasting models

• Models to apply for forecasting returns, inventory and LOE impact

• Post-acquisition intangible asset valuation

• Financial analysis around M&A transactions

Steve Vernaleken, Manager, Value Driver Sales Forecasting, Financial Decision Support, Sanofi Aventis Pharmaceuticals

3:00 Networking & Refreshment Break

3:30 R&D Project Financial Planning, Analysis and Budget Control • Managing project finances and avoiding major

deviations from budgets and/or forecasts

• Best practices for budget considerations when dealing with alliance partners

• Working effectively with collaborators and for the exchange of actuals, budgets and forecasts related to R&D

• Developing financial scenarios/outcomes for R&D programs

• Communicating effectively to management and the R&D leadership teams

Wanda Ionescu, CEO, R&D Logic

4:15 Sales/Revenue Forecasting and Contract Analytics That Drive Profitability• Best practices for revenue cycle and commercial

contract analytics

• Strategies to build forecasts with greater precision to actuals, factoring in:

* changes in demand and competitive landscape

* discount estimates and a robust accrual methodology

* actuals that meet GAAP criteria

• Opportunities, through analytics, to drive up profitability

Jagadesh Rajan, Vice President of Finance, Virtus Pharmaceuticals, LLC

5:00 Close of FP&A Summit

Please Join Us for a Welcoming Reception Immediately Following the Close of the Summit & Seminars

PHARMA/BIO

FINANCIAL PLANNING and ANALYSIS

4

MONDAY, MARCH 16, 2015 CHOOSE FROM MULTIPLE OFFERINGS

CONGRESS ATTENDEES CHOOSE FROM TWO PRE-CONGRESS LEARNING SEMINARS

Please Join Us for a Welcoming Reception Immediately Following the Close of the Summit & Seminars 5

1:30 Seminar Leaders’ Welcome and Opening Remarks

The complexities of technical accounting and financial reporting within the pharmaceutical/biotech/medical technology industry are addressed in this 201 Seminar, and is an excellent industry primer for even the most seasoned accounting and finance professionals. This intermediary course addresses the key nuances, specific regulations and emerging trends impacting the life sciences accounting community. Gain professional insight into areas of highest exposure and materiality, and understand the key accounting and financial reporting implications.

I. Introduction to the Life Sciences Industry• R&D trends — Products, FDA approvals,

market value and headlines• Governing bodies and key regulations

II. Delve into Nuances of Contract Relationships and Statutory/Government Pricing • Contracting and managed markets• Distribution channel arrangements• Government pricing and Affordable Care

Act implications

3:30 Networking and Refreshment Break

III. Basic Revenue Principles Applied to Pharma• R&D collaboration accounting models• Licensing accounting

IV. Gross-to-Net Principles• New product launch• Product return estimates• Forecasting Part D coverage gap

Seminar Leaders:

Matt Riviello, Partner, Deloitte & Touche LLP

Bruce Rucks, Senior Manager, Deloitte & Touche LLP

Mike Lombardo, Senior Manager, Deloitte & Touche LLP

5:00 Close of 201 Boot Camp Seminar

1:30 Seminar Leaders’ Welcome and Opening Remarks

The industry faces a higher bar for assurance, internal controls, documentation and disclosure. This Seminar explores new and emerging risk factors, specific to life science manufacturers, and delves into the frameworks and key business processes necessary for mitigating and managing these risks. Gain important insights to best position your organization to mitigate business risks (domestic and global), as well as strategies to maximize the effectiveness and the value of an internal control framework.

I. Exploration of Prevailing and Evolving Risks• 3rd party relationship oversight and due diligence• Open payment reporting and transparency• Global business risks and FCPA • SEC comment letter topics —

MD&A, Revenue Recognition, Intangibles, Fair Value Measurements, etc.

II. Deep Dive on Documentation and Business Requirements• Next-generation of SOX compliance• COSO 2013 framework adoption• Ways to derive added value while meeting

new requirements

3:30 Networking and Refreshment Break

III. Industry Panel on Working through Change• Best practices for aligning the organization for

successful implementation• Internal Controls — Mapping and establishing an

effective and adequate framework• Documentation in support of SOX and

governance requirements• Strategies to mitigate risk while maximizing

business benefitSeminar Leaders:Marc Miller, Partner, Advisory Risk Consulting Leader – Life Sciences, KPMG LLPAngela Hoon, Principal, ERM & GRC, KPMG LLPVishal Mehta, Director, ERM & GRC, KPMG LLP David Levi, Executive Director, Business Controls, Bristol-Myers SquibbJason Pitofsky, Senior Director of Accounting, Regeneron Pharmaceuticals, Inc.

5:00 Close of GRC Excellence Seminar

201 Boot Camp — Accounting and Financial Reporting

in Life Science Companies

A GRC Excellence — Mitigating Risk and Strategies

for Internal Controls

B

11:45 Summit Facilitator’s Welcome Remarks

For the first time ever, a unique opportunity for visibility, meaningful learning and hands-on experience with various financial automation tools and systems — Attendees of the annual Accounting and Reporting Congress are invited to engage directly with key solution providers in small group demonstrations. Company needs are matched with capabilities in a highly interactive and intimate setting. Participants not only see

and experience the systems, but also walk away with a tool kit that illustrates the nuances of various automation systems and solutions directly related to prevailing industry challenges.

• Who Does What — Features and facets are explored* interface capabilities* data reporting and dashboard screenshots* forecasting and analytic features

and capabilities

• Solution Synergies — Identify tools that mirror your needs and existing system infrastructure

* perform needs assessments

* compile a tool kit that illustrates the solution landscape

12:00 Live Demonstration ONE

12:30 Live Demonstration TWO

1:00 Live Demonstration THREE

FINANCIAL SOLUTIONS — TOOL BOX AND SYSTEM SHOWCASE

11:30 Main Registration

7:30 Breakfast and Main Registration

8:00 Chairperson’s Welcome and Opening Remarks

Cathy Engelbert, Partner, Chairman and CEO, Deloitte & Touche LLPMs. Engelbert has twenty-eight years of experience at Deloitte, including sixteen years as a Partner serving several of the world’s leading life sciences and pharmaceutical companies, and advises multinational companies on financial instrument accounting matters. She is currently a member of the Deloitte LLP board of directors and serves on the board’s Strategic Investment and Finance & Audit Committees. Ms. Engelbert previously served on the Risk and Regulatory & Government Relations Committees. She holds a bachelor’s degree in accounting from Lehigh University. She is a CPA and is a member of the American Institute of CPAs. She is also a member of the Financial Accounting Standards Advisory Council, the Accounting Advisory Board for Lehigh University, and is a board executive member for a not for profit organization.

8:20 OPENING KEYNOTE PANEL Innovation Tailwinds — New Thinking and Transformative Models Driving the Enterprise and Shareholder Return• Managing investor/stakeholder relations• Evolving tax strategy• Driving integration of information across the enterprise• Inspiring and innovating within the finance team• Supporting, managing and mitigating enterprise risk• Market factors and industry trends impacting the

business today and in the future

Moderator:

Karen C. Young, U.S. Pharmaceutical and Life Sciences Assurance Leader, PwC

Panelists:

Robin Washington, Chief Financial Officer, Gilead Sciences

J. Kevin Buchi, President and Chief Executive Officer, TetraLogic Pharmaceuticals

William D. “Chip” Baird, Chief Financial Officer, Amicus Therapeutics

9:20 New and Emerging Models for Fueling Growth and Propelling Innovation• Deal activity, trends and impact — Assessing the M&A

landscape and projecting the path ahead• Current thinking around changing healthcare

landscape and impact on R&D investment• Funding models and investment runways, particularly

within the rare disease space• What we’ve seen and expectations for the future• Company creation, deal making and venture investing

Philip S. Ross, Managing Director, Healthcare Investment Banking, J.P. Morgan

Jean-Francois Formela, Partner, Atlas Ventures

10:00 Networking and Refreshment Break

10:30 Industry Luminary Addresses Gain insight into the industry’s foremost minds as influential and impactful leaders in Finance, Accounting and Tax Policy sound off on the pressing issues impacting the business.

Moderator:

Dave DeMarco, Partner, Northeast Life Sciences Leader, Ernst & Young LLP

10:45 Translating Accounting and Technical Regulations into Business and Deal Strategy — The Role of Accounting in Shaping ValueStephen Rivera, Worldwide Senior Director of Financial Compliance and Procedures, Johnson & Johnson

11:15 Transforming and Leading through Transformation — The Role of the Finance Organization During Periods of Growth and ChangeRobin Washington, Chief Financial Officer, Gilead Sciences

11:45 Taking Strides in Corporate Tax Reform — Tax Policy’s Impact on Business Decisions• Broad fiscal challenges and U.S. tax reform —

Key elements and potential outcomes• The significance of corporate income taxes, drug fees

and rebates paid by life science industry

David Lewis, Chief Tax Officer, Eli Lilly & Co

12:15 Moderated Q&A with Luminary Speakers

12:30 Luncheon

REGULATORY AND OVERSIGHT EXTENDED SESSION

Moderator:

Christine Q. Davine, National Director of SEC Services, Deloitte & Touche LLP

1:30 Review of SEC Comments in Life Sciences and Q&A with SEC• In-depth discussion and analysis on SEC Hot Topics,

including:* disclosures* revenue recognition* business vs. asset* intangibles* fair value measurements

Joel Parker, Accounting Branch Chief, Division of Corporation Finance, U.S. Securities and Exchange CommissionMr. Parker is an Accounting Branch Chief in the Office of Health Care and Insurance within the Division of Corporation Finance. He joined the Division of Corporation Finance in August 2004 as a Staff Accountant in the Office of Health Care and Insurance and became a Branch Chief in that office in April 2005. From November 2005 to May 2007, Mr. Parker served as the Chief Accounting Officer for Bon Secours Health System. He returned to his former position at the SEC in May 2007. Prior to initially joining the staff of the SEC, Mr. Parker was an Audit Senior Manager with KPMG LLP. Mr. Parker graduated with a Bachelor of Science degree in Accounting from The Pennsylvania State University and is Certified Public Accountant in Pennsylvania.

2:30 Technical Guidance Updates from FASB and Initiatives Ahead Cullen Walsh, Assistant Director, Financial Accounting Standards Board (FASB)Cullen D. Walsh was named an assistant director of the Financial Accounting Standards Board (FASB) in 2013. He is responsible for managing the Board’s research agenda, which includes projects where the Board has directed the staff to perform pre-agenda research; overseeing international monitoring of projects undertaken by other standards setters; and managing the execution of implementation working groups, including the revenue recognition transition resource group.

2:50 What to Expect from the PCAOB and Impact on PreparersJay Hanson, Board Member, Public Company Accounting Oversight Board (PCAOB) Mr. Hanson was appointed by the Securities and Exchange Commission to be a member of the Public Company Accounting Oversight Board in January 2011. Prior to joining the Board, Mr. Hanson spent nearly 32 years at McGladrey & Pullen, LLP. Mr. Hanson served as a member of the Emerging Issues Task Force of the Financial Accounting Standards Board (FASB) from 2006 to 2011. He also was a member of the Financial Reporting Executive Committee of the American Institute of Certified Public Accountants (AICPA) from 2005 to 2011, serving as Chairman from 2008-2011.

3:15 Networking and Refreshment Break Hosted by:

TUESDAY, MARCH 17, 2015 MAIN CONGRESS

6

TUESDAY, MARCH 17, 2015 WORKSHOPS

• Acquisition trends and valuation approaches for:* inventory * divestitures * tax Inversions* contingent consideration* asset-like acquisitions

• Assessing available models in approaching contingent consideration

• Strategies for applying various models• Best practices under development

• Best methods and interpretations to various valuation models and approaches to auditing the information

• Industry perspectives — Lessons learned in valuing assets, contingent consideration and driving deal strategy

• IPR&D

• Contingent consideration

Workshop Leaders:Michelle Mittelsteadt, Partner, Life Sciences Valuation & Business Modeling, Ernst & Young LLPTatjana Heller, Senior Manager, Life Sciences Valuation & Business Modeling, Ernst & Young LLPChris Reinholz, Senior Manager, Life Sciences Valuation & Business Modeling, Ernst & Young LLPWorkshop Speakers and Panelists:James D’Arreca, Chief Accounting Officer, Actavis, Inc.

3:45 A U D I E N C E C H O O S E S F R O M F I V E A F T E R N O O N W O R K S H O P S

VALUATION MODELS AND METHODOLOGIES

Please Join Us for a Cocktail Reception Immediately Following the Close of Workshops Hosted by:

5:45 C L O S E O F W O R K S H O P S

7

• Collaborative agreements and asset acquisitions

• Recognition of milestone payments, performance metrics and royalties

• Accounting for licenses of intellectual property

Workshop Leaders:Phil Pfrang, Lead Partner of the Health Care & Life Sciences Merger & Acquisitions Transaction Services Group, Deloitte & Touche LLP

Jeff Ellis, Partner, Deloitte & Touche LLP

Workshop Speakers and Panelists:Daphne Quimi, Amicus TherapeuticsRobert Owens, Assistant Controller, Bristol-Myers Squibb

I. Practical Application of the New Revenue Standard

• Complexity of issues impacting life science companies

• Key ‘watch-outs’ and how to deal with uncertainty

• Establishing the team and talent needed to align the organization for the new revenue standard

• Setting up an implementation — Needed tools and project management

II. Effective Management and Oversight of Collaboration Agreements

• Real life implications from inadequate and ineffective oversight over contractual obligations

• The role of finance/accounting personnel during contract negotiation

• How to effectively hand off contract oversight responsibilities from deal teams following the execution of agreements

• How a consistent and centralized oversight program can minimize financial risk and exposure

• Best practices to establish oversight processes

• Strategies to consistently report and monitor financial and operational obligations

• Consideration as to whether to exercise audit rights — If and when?

• Technology considerations to increase efficiency and effectiveness of monitoring and reporting obligations

Workshop Leaders:Pamela Yanakopulos, Partner, Capital Markets and Accounting Advisory Services, (CMAAS), PwCJoe Braido, Director, Forensic Services, PwC

• Critical updates on government pricing programs, Medicaid, Tricare and 340B

• Product estimates for new launches/returns

• Accounting for rebates, price protection, discounts and incentives

• Forecasting Coverage Gap liability

• Estimate models for Branded Pharma FeeWorkshop Leader:Jennifer Cain, Assurance Senior Manager, PwC

Workshop Speakers and Panelists:Patrick R. Coyle, Senior Finance Manager, Oncology, Bayer HealthCare Pharmaceuticals Inc.

Larry Breen, Director of Financial Planning and Analysis/Revenue Analytics, Sunovion PharmaceuticalsJeff Miller, Associate Director, Revenue Accounting, Impax LabsDavid Levi, Executive Director, Business Controls, Bristol-Myers Squibb

A

TRANSACTION ACCOUNTINGB

REVENUE PLAYBOOK — PROJECT PREPAREDNESS AND CONTRACT REVIEWC

GROSS-TO-NET MASTER CLASSD

• Bridging the divide between valuations done for financial reporting and tax/transfer pricing

• Understanding whether valuations done for financial reporting can be used for transfer pricing or tax planning purposes

• Hot button issues surrounding intangible asset valuation in transactions, such as:

* how can the identification of intangible assets for financial reporting be leveraged to identify transfer pricing opportunities and risks during acquisition due diligence?

* what are the methods used to value intangible assets and how do they differ depending on the valuation purpose?

* what benefits can be realized by performing simultaneous valuations for financial reporting and transfer pricing purposes?

Workshop Leaders:

Jill Weise, Managing Director, Duff & Phelps

Andreas Chrysostomou, Managing Director, Duff & Phelps

ASSET VALUATION AND TAX/TRANSFER PRICING IMPACTSE

TECHNICAL ACCOUNTING AND PREPARER BEST PRACTICESI

A T T E N D E E S C H O O S E B E T W E E N 2 T R A C K S , W I T H O P P O R T U N I T Y T O M O V E B E T W E E N S E S S I O N S

8:30 Track Chairperson’s Welcome and Review of Day One

Matt Riviello, Partner, Deloitte & Touche LLP

8:45 PANEL DISCUSSION New Revenue Standard — Industry Strategies and Benchmarking for Assessment, Application and Implementation• Understanding specific industry concerns

for example:* collaborations in scope or not?* collectibility and implicit price concessions* variable consideration and expected value* licenses and application of the exemption for

usage based royalties* synthetic FOB destination and identifying

performance obligations• Strategies for planning an efficient

project including:* identifying appropriate revenue streams* educating the business and stakeholders* organizing cross functional teams including

tax and systems* understanding the new disclosure

requirements and transition options* use of available tools

Moderator:

Tim Gordon, Americas Leader of Financial Accounting Advisory Services — Life Sciences, Ernst & Young LLP

Panelists:

Stephen Rivera, Worldwide Senior Director of Financial Compliance and Procedures, Johnson & Johnson

Robert Owens, Assistant Controller, Bristol-Myers Squibb

Tom Cunningham, Assistant Controller, Merck & Co

9:45 Practical Application of Accounting Models for Licensing Arrangements • Out-licensing and technical

accounting considerations • Accounting structures/models for

licensing arrangements• Principal agent consideration

(gross or net revenue)

• Customer payments• Variable interest entity and consolidation issues• Business combination versus asset acquisition

Cindy Anderson, Director of Financial Reporting and Compliance, Alexion Pharmaceuticals

Brent Sabatini, Director of Technical Accounting, Amgen

10:30 Networking and Refreshment Break

11:00 Business Combinations and Purchase Accounting — Strategies to Optimize Transactions • Complexities of accounting for large

business combinations• Effectively control purchase accounting

adjustments related to transactions• Account for adjustments to fair value of

purchased assets• Implement monitoring controls and assess

relative risk• Strategies for calculating deferred taxes,

depreciation, amortization and currency translation adjustments

Christine Zeikel, Business Valuation Principal, Deloitte FAS LLP

Prateep Menon, Partner, Deloitte FAS LLP

11:45 Collaboration Accounting — Industry Cases• Common elements and prevailing models for

accounting for collaborations• What are companies doing today to

account and report on — Current challenges and survey results

• Key accounting questions and considerations for both parties

• Tax considerations — Deal structure, licensee structure (is a separate legal entity set up for collaboration, etc.)

• Valuation considerations — Discount rates, projections

Isabelle Freret-Fresnel, Executive Director, FAAS, Ernst & Young LLP

1:00 Close of Track I

WEDNESDAY, MARCH 18, 2015 TRACKS

1:00 C L O S E O F C O N F E R E N C E

W W W . C B I N E T . C O M / A C C O U N T I N G8

A T T E N D E E S C H O O S E B E T W E E N 2 T R A C K S , W I T H O P P O R T U N I T Y T O M O V E B E T W E E N S E S S I O N S

8:30 Track Chairperson’s Welcome and Review of Day One

Chris Cooper, Partner, Deloitte & Touche LLP, and National Audit Life Sciences Sector Leader

8:45 PANEL DISCUSSION Establishing an Optimal Financial Reporting Process Post-IPO — Strategies to Excel in the Public Arena• Developing a finance team to be able to

handle tighter reporting deadlines and increased compliance requirements

• Evaluation of finance function staffing needs and levels

• Developing internal control environment that meets public company compliance requirements

• Auditor’s top-down approach and what to expect in an audit

• Ensuring adequate controls and effective documentation

• Evaluating and addressing identified deficiencies• Organizational process strategies to comply with

reporting and financial close cycle timelines

Moderator:CFGI

Panelists:

Stephen Garbacz, Executive Director of Finance, EpizymeBrian Hahn, Chief Financial Officer, GlycomimeticsBarbara Duncan, Chief Financial Officer, Intercept Pharmaceuticals, Inc.

9:45 Strategies to Optimize Licensing Deals and IP Arrangements — Tax Considerations and Royalty Payment Reviews in Licensing Deals• Successful business models for licensing IP,

patented technology or early-stage R&D assets• Capitalizing on tax-efficient strategies and

leveraging intellectual property• Accounting treatment and considerations for

determining/calculating royalties• Best practices in conducting royalty audits to

identify underpayments and inaccuracies John F. Lanza, CPA, Partner, Northeast, McGladrey LLPRita Chung, International Tax Senior Manager, McGladrey LLP

10:30 Networking and Refreshment Break

11:00 Monetizing Early-Stage R&D Assets • Analysis of traditional funding mechanisms

for early-stage R&D assets and how that community is evolving

• New mechanisms being deployed by the investor community to fund early stage R&D assets

• Insight into pharma’s increasing involvement in the funding of early stage R&D assets

• Highlights of early stage R&D assets that have funded/exited and insights into how those deals happened

Benjamin Perkins, Partner, Life Science Lead Advisory Services, Ernst & Young LLP

11:45 Stock Options and Equity Compensation — Key Considerations for Valuation • Valuation of equity and stock compensation

• Estimating a share price when there are multiple securities

• Considerations for what might generate an equity award modification

Andreas Chrysostomou, Managing Director, Duff & Phelps

Amy Thomas, Director, Duff & Phelps

1:00 Close of Track II

WEDNESDAY, MARCH 18, 2015 TRACKS

FINANCE MODELS AND INVESTMENT STRATEGIES II

1:00 C L O S E O F C O N F E R E N C E

W W W . C B I N E T . C O M / A C C O U N T I N G 9

A GREAT PLACE TO MEET YOUR MARKET!Take advantage of the best opportunity to meet potential clients face-to-face. Build relationships while demonstrating thought leadership and sharing expertise.

For more information on how to position your company as a sponsor or exhibitor, contact Lauren Moras at 339-298-2172 or email lauren.moras@cbinet.com

BPIADDITIONAL SPONSORS

2015 MEDIA PARTNERS

W W W . C B I N E T . C O M / A C C O U N T I N G10

SPONSORS & EXHIBITORS REGISTRATION INFORMATION

ABOUT OUR LEAD SPONSOR In the United States, Deloitte* has more than 60,000 professionals with a single focus: serving our clients and helping them solve their toughest problems by offering audit, tax, consulting, and financial advisory services. Globally, through the Deloitte Touche Tohmatsu Limited (DTTL) network of member firms, Deloitte can leverage the knowledge and experience of a workforce of 200,000 professionals in more than 150 countries.

Deloitte & Touche LLP, which includes the Audit and Enterprise Risk Services business of Deloitte, provides audits and reviews of financial statements and reporting on internal controls, as well as helps organizations identify and manage risks and opportunities to improve business performance, strengthen controls, and enhance corporate governance.

At Deloitte, we focus on helping clients transform their strategic vision into innovative, practical health care and life sciences solutions that support their business goals today and tomorrow. Deloitte’s Life Sciences and Health Care practice is among the largest in the world, leveraging the extensive knowledge, skills and experience of over 7,000 professionals in 80 countries around the world and approximately 4,500 professionals in the United States. Our practice offers a distinctive menu of professional services delivered in an integrated approach that addresses all segments of the health plan, health provider and life sciences industries. For more information on Deloitte’s services, please visit www.deloitte.com.

*As used in this document, “Deloitte” means Deloitte LLP and its subsidiaries. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

ABOUT OUR STRATEGIC CORPORATE SPONSOR

PwC’s Pharmaceutical and Life Sciences Industry Group is dedicated to delivering effective solutions to the complex strategic, operational and financial challenges facing pharmaceutical, biotechnology and medical device companies. We provide industry-focused assurance, tax and advisory services to build public trust and enhance value for our clients and their stakeholders. More than 195,000 people in 157 countries across our network of firms share their thinking, experience and solutions to develop fresh perspectives and practical advice. Visit us at www.pwc.com/us/pharma and www.pwc.com/us/medtech.

ABOUT OUR STRATEGIC SILVER SPONSORLife Sciences companies are in the midst of a highly active and competitive transaction market. EY’s Life Sciences teams help senior finance executives navigate the complexities of transformational change, whether that change is a result of transactions that reshape the business model, enterprise-wide projects that require integration across the entire organization or significant regulatory shifts that affect the financial operations of the overall business. We work with you to make the right decisions by combining your organizational knowledge with the thorough analysis of our experienced professionals, who can provide insights into the trends and developments affecting pharmaceutical, biotechnology and medical device companies in the sector.

It is one way that we are helping to build a better working world.

VENUE

Hyatt Regency Penn’s Landing201 S. Columbus Blvd. Philadelphia, PA 19106Reservations: 888-421-1442Direct Line: 215-928-1234

SUBSTITUTION & CANCELLATION

Your registration may be transferred to a member of your organization up to 24 hours in advance of the conference. Cancellations received in writing on or before 14 days prior to the start date of the event will be refunded, less a $399 administrative charge. No refunds will be made after this date; however, the registration fee less the $399 administrative charge can be credited to another CBI conference if you register within 30 days from the date of this conference to an alternative CBI conference scheduled within the next six months. In case of conference cancellation, CBI’s liability is limited to refund of the conference registration fee only. CBI reserves the right to alter this program without prior notice. Please Note: speakers and agenda are subject to change. In the event of a speaker cancellation, every effort to find a suitable replacement will be made without notice. The opinions of the conference faculty do not necessarily reflect those of the companies they represent or CBI.

ACCOMMODATIONS:

To receive CBI’s special discounted hotel rate:Online: cbinet.com/accountingPhone reservations: 888-421-1442 (mention CBI’s Accounting)

Book Now! The Hyatt Regency Penn’s Landing is accepting reservations on a space and rate availability basis. Rooms are limited so please book early. All travel arrangements are subject to availability.

TEAM DISCOUNT:

Attend this conference FREE if you bring THREE registered colleagues from your organization or external to your organization (enables cross-company teams). Team registrations must be made at the same time to qualify. To receive the team discount you must register with our customer service department by calling 339-298-2100.

* Advantage pricing rates do apply when applicable. Offer may not be combined with any other special pricing promotions. Offer may be used at CBI co-located events.

SATISFACTION GUARANTEED:

CBI stands behind the quality of its conferences. If you are not satisfied with the quality of the conference, a credit will be awarded towards a comparable CBI conference of your choice. Please contact 800-817-8601 for further information. Advanced preparation for CBI conferences is not required.

REGISTRATION FEE:

Advantage Pricing*

Congress — $2,299 Congress + FPA Summit — $2,599 FPA Summit Only — $1,299

Standard Pricing*

Congress— $2,599 Congress + FPA Summit — $2,899 FPA Summit Only — $1,599

*Fee includes continental breakfast, lunch, wine and cheese reception, refreshments and conference documentation. Please make checks (in U.S. funds drawn on a U.S. bank) payable to: CBI. (No personal checks accepted.) PLEASE NOTE: All advertised discounts are taken from the final, Standard Rate.

F O U R W AY S T O R E G I S T E R N O W !

3PHONE

Christian Alongi 339-298-2131

1WEBSITE

cbinet.com/accounting

2EMAIL

christian.alongi@cbinet.com

4LIVE CHAT

cbinet.com/accounting

PC15139

Register by 1/16/15 and SAVE $300!

REGISTRATION INFORMATION

11

“Thiscontinuestobethepremierconferencethatallfinancialreportingpersonnel from pharma/biotech should participate in each year.”

— Chief Accounting Officer, Eli Lilly & Co.

PROGRAM CONTENT: Sharon Langan Team Leader, CBI’s Financial Series sharon.langan@cbinet.com

339-298-2115

PROGRAM REGISTRATION: Christian Alongi Delegate Sales Representative,

CBI’s Financial Series christian.alongi@cbinet.com

339-298-2131

PROGRAM SPONSORSHIP: Lauren Moras

Business Development Manager, CBI’s Financial Series

lauren.moras@cbinet.com 339-298-2172

YOUR KEY POINTS OF CONTACT:

W W W . C B I N E T . C O M / A C C O U N T I N G

MARCH 16-18, 2015 | HYATT REGENCY PENN’S LANDING | PHILADELPHIA, PA

R E G I S T E R B Y J A N U A R Y 1 6 , 2 0 1 5 A N D S A V E $ 3 0 0 !

LIFE SCIENCES

CONGRESSACCOUNTING & REPORTING

The Industry Standard Accounting Event Driving Practice Alignment and Financial Excellence

CPE Credits Available!Pending Approval

CBI 70 Blanchard Road Burlington, MA 01803

WW

W.

CB

IN

ET

.C

OM

/A

CC

OU

NT

IN

G

RE

GIS

TE

R B

Y J

AN

UA

RY

16, 2

015

AN

D S

AV

E

$30

0!

Mo

st Custo

miza

ble

Co

ngre

ss Ye

t! Fea

tures 4 Pre

-Co

nfere

nce

Summ

its, 5 In-D

ep

th Wo

rkshop

s and

2 Trac

k Op

tions! Plus, Ea

rn CPE C

red

its!

MA

RC

H 1

6-1

8, 2

01

5 |

HYA

TT RE

GE

NC

Y P

EN

N’S LA

ND

ING

| P

HILA

DE

LPH

IA, P

A

•

Gro

ss-to-N

et m

od

els fo

r fore

ca

sting

Co

vera

ge

Ga

p a

nd

Bra

nd

ed

Pha

rma

Fee

•

SEC c

om

me

nt le

tter to

pic

an

alysis —

MD

&A

, Re

ven

ue

R

ec

og

nitio

n, In

tan

gib

les, Fa

ir Va

lue

Me

asu

rem

en

ts

•

Inte

rna

l Co

ntro

l fram

ew

orks th

at m

ap

an

d m

itiga

te

bu

sine

ss risks

•

Do

cu

me

nta

tion

strate

gie

s alig

ne

d w

ith SO

X a

nd

C

OSO

req

uire

me

nts

•

Tran

sform

ative

ap

pro

ac

he

s to ta

x strate

gy

•

De

al a

ctivity a

na

lysis an

d M

&A

ou

tloo

k

•

Va

lua

tion

mo

de

ls for IPR

&D

asse

ts, co

ntin

ge

nt c

on

side

ratio

n

an

d im

pa

ct o

n d

ea

l strate

gy

•

Tran

sac

tion

ac

co

un

ting

for in

/ou

t lice

nsin

g a

rran

ge

me

nts

•

Co

ntra

ct re

view

for ro

yalty a

gre

em

en

ts an

d e

xerc

ising

a

ud

it righ

ts

•

Ne

w re

ven

ue

stan

da

rd a

nd

strate

gie

s for a

ssessm

en

t, a

pp

lica

tion

an

d im

ple

me

nta

tion

•

Risk-sh

are

R&

D m

od

els a

nd

asse

t tran

sac

tion

s

•

Ac

co

un

ting

ap

pro

ac

he

s an

d va

lua

tion

for sto

ck o

ptio

ns

an

d e

qu

ity co

mp

en

satio

n

PIO

NE

ER

ING

PE

RS

PE

CTIV

ES

INC

LUD

E:

Ac

tavis, p

lc • A

lexio

n • Am

ge

n • Am

icus The

rap

eutic

s • Atla

s Ve

ntures • Bristo

l-Mye

rs Squib

b

Cha

rles Rive

r Lab

s • De

loitte

• Eli Lilly & C

o. • Ep

izyme

• Ernst & Y

oung

LLP • FASB

Gile

ad

Scie

nce

s • Glyc

om

ime

tics • Im

pa

x Lab

s • Interc

ep

t Pharm

ac

eutic

als • Jo

hnson &

Johnso

n J.P. M

org

an • K

PMG

• Me

rck &

Co

• Myla

n • Reg

ene

ron • Suno

vion

Tetra

Log

ic Pha

rma

ce

utica

ls • PCA

OB • Pw

C • SEC

LEA

D SPO

NSO

RSTR

ATEG

IC

CO

RP

OR

ATE

SPO

NSO

R

STRA

TEGIC

SILV

ER

SP

ON

SOR

LIFE S

CIE

NC

ES

CO

NG

RE

SS

AC

CO

UN

TING

& REPO

RTING

The Industry Standard Accounting Event D

riving Practice Alignm

ent and Financial Excellence

CPE Credits Available!

Pending Approval

Ne

w This Y

ea

r!P

HA

RM

A/B

IO

FINA

NC

IAL PLA

NN

ING

and

AN

ALYSIS

IN-D

EPTH

CO

NTEN

T ON

HO

T TOP

ICS, IN

CLU

DIN

G

A P

re-C

on

gre

ss Su

mm

it on

Ma

rch

16

th

Additional CPE Credits!Pending Approval

ANY QUESTIONS OR TO REGISTERCALL Christian Alongi 339-298-2131

or FAX TO MY ATTENTION 781-939-2694email: christian.alongi@cbinet.com